Kellie Charles received her PhD in 2004 from the University of Sydney, she is now a Associate Professor and Head of the Cancer Therapeutics Research Group at the same institution.  A/Prof Charles has more than 15 years’ experience in clinical trials and translational cancer research both nationally and internationally and her research is evidenced in many premier cancer journals.

Currently, Kellie is the lead chief investigator of The Sydney 1000 Colorectal Cancer Study, and leads a multidisciplinary team of 200 researchers across the University of Sydney and Sydney Health Partner hospitals.


Research Interests

Kellie is interested investigating the interactions between malignant cells and immune cells that regulate tumour progression. She carries out translational and clinical studies aiming to identify new molecular targets in cancer and in collaboration with biological chemists at The University of Sydney design and evaluate new cancer therapeutic agents.

Unit Seed Grant. The STRICT (Simvastatin Therapy for Reducing Inflammation in Colorectal Cancer Trial) Pilot Study

Northern Translational Cancer Research 2013

The STRICT (Simvastatin Therapy for Reducing Inflammation in Colorectal Cancer Trial) Pilot Study

Bosch Institute Translational Grant in Aid (CIA)

A high-throughput, bright-field and fluorescence digital slide scanning platform and service

University of Sydney 2013

Robotic High Throughput Western Analysis for the Open Access, Multi-User Sydney Cancer Research Core Facility

University of Sydney 2013

Equipment Grant

NHMRC 2012

Cancer Research Fund Research Infrastructure Grant

University of Sydney 2012

Career Development Fellowship

Cancer Institute NSW 2010

Infrastructure Grant

Cancer Institute NSW 2010

Equipment Gift

Ramaciotti Foundation 2010

Innovation Grant

Cancer Institute NSW 2009

New Investigators Grant

Ramaciotti Foundation 2008

Early Careers Researchers Grant

University of Sydney, Faulty of Medicine 2008

Year Award/ Honour Institution
2014 Best Oral Presentation Hunter Translational Cancer Research Meeting
2011 PhD Scholarship Rotary Health
2009 Denis Wade Johnson and Johnson New Investigator Award Australasian Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT)
2005 GlaxoSmithKline Oustanding Clinical Scholar in Training Award American Association for Cancer Research
2003 Best PhD Student Oral Presentation at the ASCEPT Annual Conference ASCEPT
2001 Bishop Scholarship Dept of Pharmacology
2001 Australian Postgraduate Award Scholarship

Shinko, D., Diakos, C., Clarke, S., Charles (nee Slaviero), K. (2017). Cancer-Related Systemic Inflammation: The Challenges and Therapeutic Opportunities for Personalized Medicine. Clinical Pharmacology & Therapeutics, 102(4), 599-610. [More Information]

Charles (nee Slaviero), K., Harris, B., Haddad, C., Clarke, S., Guminski, A., Stevens, M., Dodds, T., Gill, A., Back, M., Veivers, D., Eade, T. (2016). Systemic inflammation is an independent predictive marker of clinical outcomes in mucosal squamous cell carcinoma of the head and neck in oropharyngeal and nonoropharyngeal patients. BMC Cancer, 16(1), 1-13. [More Information]

Shen, C., Harris, B., Dawson, L., Charles (nee Slaviero), K., Hambley, T., New, E. (2015). Fluorescent sensing of monofunctional platinum species. Chemical Communications, 51(29), 6312-6314. [More Information]

Diakos, C., Charles (nee Slaviero), K., McMillan, D., Clarke, S. (2014). Cancer-related inflammation and treatment effectiveness. The Lancet Oncology, 15(11), e493-e503. [More Information]

Elens, L., Nieuweboer, A., Clarke, S., Charles (nee Slaviero), K., De Graan, A., Haufroid, V., Mathijssen, R., Van Schaik, R. (2013). CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmacogenomics, 14(2), 137-149. [More Information]

Elens, L., Nieuweboer, A., Clarke, S., Charles (nee Slaviero), K., De Graan, A., Haufroid, V., van Gelder, T., Mathijssen, R., Van Schaik, R. (2013). Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. Pharmacogenetics and Genomics, 23(3), 148-155. [More Information]

Guthrie, G., Charles (nee Slaviero), K., Roxburgh, C., Horgan, P., McMillan, D., Clarke, S. (2013). The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. Critical Reviews in Oncology / Hematology (online), 88(1), 218-230. [More Information]

Kulbe, H., Chakravarty, P., Leinster, D., Charles, K., Kwong, J., Thompson, R., Coward, J., Schioppa, T., Robinson, S., Gallagher, W., et al (2012). A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Research, 72(1), 66-75. [More Information]

Chua, W., Clarke, S., Charles (nee Slaviero), K. (2012). Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer. Supportive Care in Cancer, 20(8), 1869-1874. [More Information]

Chua, W., Kho, P., Moore, M., Charles (nee Slaviero), K., Clarke, S. (2011). Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. Critical Reviews in Oncology/Hematology, 79(3), 224-250. [More Information]

Chua, W., Charles (nee Slaviero), K., Baracos, V., Clarke, S. (2011). Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. British Journal of Cancer, 104(8), 1288-1295. [More Information]

Clarke, S., Chua, W., Moore, M., Kao, S., Phan, V., Tan, C., Charles (nee Slaviero), K., McMillan, D. (2011). Use of inflammatory markers to guide cancer treatment. Clinical Pharmacology & Therapeutics, 90(3), 475-478. [More Information]

Moore, M., Chua, W., Charles (nee Slaviero), K., Clarke, S. (2010). Inflammation and Cancer: Causes and Consequences. Clinical Pharmacology & Therapeutics, 87(4), 504-508. [More Information]

Chua, W., Moore, M., Charles (nee Slaviero), K., Clarke, S. (2009). Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer. Current Opinion in Molecular Therapeutics, 11(6), 611-622. [More Information]

Charles (nee Slaviero), K., Kulbe, H., Soper, R., Escorcio-Correia, M., Lawrence, T., Schultheis, A., Chakravarty, P., Thomson, R., Kollias, G., Smyth, J., et al (2009). The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans. Journal of Clinical Investigation, 119(10), 3011-2023. [More Information]

Hagemann, T., Lawrence, T., McNeish, I., Charles (nee Slaviero), K., Kulbe, H., Thompson, R., Robinson, S., Balkwill, F. (2008). “Re-educating” tumor-associated macrophages by targeting NF-κB. The Journal of Experimental Medicine, 205(6), 1261-1268. [More Information]

Brown, E., Charles (nee Slaviero), K., Hoare, S., Rye, R., Jodrell, D., Aird, R., Vora, R., Prabhakar, U., Nakada, M., Corringham, R., et al (2008). A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Annals of Oncology, 19(7), 1340-1346. [More Information]

Hagemann, T., Robinson, S., Thompson, R., Charles (nee Slaviero), K., Kulbe, H., Balkwill, F. (2007). Ovarian cancer cell–derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Molecular Cancer Therapeutics, 6(7), 1993-2002. [More Information]

Harrison, M., Obermueller, E., Maisey, N., Hoare, S., Edmonds, K., Li, N., Chao, D., Hall, K., Lee, C., Timotheadou, E., Charles (nee Slaviero), K., et al (2007). Tumor necrosis Factor α as a new target for renal cell carcinoma: Two sequential phase II trials of infliximab at standard and high dose. Journal of Clinical Oncology, 25(29), 4542-4549. [More Information]

Hagemann, T., Wilson, J., Burke, F., Kulbe, H., Li, N., Plüddemann, A., Charles (nee Slaviero), K., Gordon, S., Balkwill, F. (2006). Ovarian Cancer Cells Polarize Macrophages Toward A Tumor-Associated Phenotype. Journal of Immunology, 176(8), 5023-5032. [More Information]

Charles (nee Slaviero), K., Rivory, L., Stockler, M., Beale, P., Beith, J., Boyer, M., Clarke, S. (2006). Predicting the toxicity of weekly docetaxel in advanced cancer. Clinical Pharmacokinetics, 45(6), 611-622. [More Information]

Charles (nee Slaviero), K., Rivory, L., Brown, S., Liddle, C., Clarke, S., Robertson, G. (2006). Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clinical Cancer Research, 12(24), 7492-7497. [More Information]

Szlosarek, P., Charles (nee Slaviero), K., Balkwill, F. (2006). Tumour necrosis factor-alpha as a tumour promoter. European Journal of Cancer, 42(6), 745-750. [More Information]

Hagemann, T., Wilson, J., Kulbe, H., Li, N., Leinster, D., Charles (nee Slaviero), K., Klemm, F., Pukrop, T., Binder, C., Balkwill, F. (2005). Macrophages Induce Invasiveness of Epithelial Cancer Cells Via NF-κB and JNK. Journal of Immunology, 175(2), 1197-1205. [More Information]

Balkwill, F., Charles (nee Slaviero), K., Mantovani, A. (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell, 7(3, March 2005), 211-217. [More Information]

Charles (nee Slaviero), K., Clarke, S., McLachlan, A., Blair, E., Rivory, L. (2004). Population Pharmacokinetics Of Weekly Docetaxel In Patients With Advanced Cancer. British Journal of Clinical Pharmacology, 57(1), 44-53. [More Information]

Charles (nee Slaviero), K., Read, J., Clarke, S., Rivory, L. (2003). Baseline Nutritional Assessment in Advanced Cancer Patients Receiving Palliative Chemotherapy. Nutrition and Cancer: an international journal, 46(2), 148-157.

Charles (nee Slaviero), K., Clarke, S., Rivory, L. (2003). Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. The Lancet Oncology, 4(4), 224-232. [More Information]

Rivory, L., Charles (nee Slaviero), K., Clarke, S. (2002). Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. British Journal of Cancer, 87(3), 277-280. [More Information]

Rivory, L., Charles (nee Slaviero), K., Hoskins, J., Clarke, S. (2001). The erythromycin breath test for the prediction of drug clearance. Clinical Pharmacokinetics, 40, 151-158.

Rivory, L., Charles (nee Slaviero), K., Seale, J., Hoskins, J., Boyer, M., Beale, P., Millward, M., Bishop, J., Clarke, S. (2000). Optimizing the erythromycin breath test for use in cancer patients. Clinical Cancer Research, 6, 3480-3485.

Diakos, C., Charles (nee Slaviero), K., Chua, W., Howell, V., Clarke, S. (2015). Biomarkers in Metastatic Colorectal Cancer. In Victor R. Preedy and Vinood B. Patel (Eds.), Biomarkers in Cancer, (pp. 601-629). Dordrecht: Springer. [More Information]

For more information please contact,

Phone: 02 9036 5239

Email: [email protected]

Find out more ..